VIABLE CREDIT FOR SMALL OPERATIONS

Agricultural Finance,

Mini-rack testbed evaluation

The goal was to characterize the Health Maintenance Facility (HMF)-like mini-racks and drawers onboard the KC-135 as a test bed for the Space Station Freedom HMF racks. An additional goal was to evaluate the attachments, mounting points, and inner drawer assemblies of the mini-racks for various medical equipment and supplies. Results and recommendations are given

Effect of Sucralfate on the Relative Bioavailability of Enrofloxacin and Ciprofloxacin in Healthy Fed Dogs

Background: Sucralfate impairs absorption of ciprofloxacin and other fluoroquinolones in humans, but no sucralfate-fluoroquinolone interaction has been reported in dogs. Veterinary formularies recommend avoiding concurrent administration of these medications, which might impact compliance, therapeutic success, and resistance selection from fluoroquinolones. Objectives: To determine whether a drug interaction exists when sucralfate is administered to fed dogs concurrently with ciprofloxacin or enrofloxacin, and whether a 2 hour delay between fluoroquinolone and sucralfate affects fluoroquinolone absorption. Animals: Five healthy Greyhounds housed in a research colony. Methods: This was a randomized crossover study. Treatments included oral ciprofloxacin (C) or oral enrofloxacin (E) alone, each fluoroquinolone concurrently with an oral suspension of sucralfate (CS, ES), and sucralfate suspension 2 hours after each fluoroquinolone (C2S, E2S). Fluoroquinolone concentrations were evaluated using liquid chromatography with mass spectrometry. Results: Drug exposure of ciprofloxacin was highly variable (AUC 5.52-22.47 h ?g/mL) compared to enrofloxacin (AUC 3.86-7.50 h ?g/mL). The mean relative bioavailability for ciprofloxacin and concurrent sucralfate was 48% (range 8-143%) compared to ciprofloxacin alone. Relative bioavailability of ciprofloxacin improved to 87% (range 37-333%) when sucralfate was delayed by 2 hours. By contrast, relative bioavailability for enrofloxacin and concurrent sucralfate was 104% (94-115%).Citation: KuKanich, K., KuKanich, B., Guess, S. and Heinrich, E. (2015), Effect of Sucralfate on the Relative Bioavailability of Enrofloxacin and Ciprofloxacin in Healthy Fed Dogs. Journal of Veterinary Internal Medicine. doi: 10.1111/jvim.1379

Finite size effects on the Poynting-Robertson effect: a fully general relativistic treatment

Ever since the first discovery of Poynting and Robertson, the radiation source has been treated as merely a point. Even in a very few studies where the size of the source has been taken into account, the treatment of the problem remained largely non-relativistic. In the present work, we address the issue of the finite size effects on the Poynting-Robertson effect in a fully relativistic manner for the first time. As a result, the emergence and the characteristic of the critical point/suspension orbit can be studied in a systematic and detailed manner.Comment: 11pages, 3figure

Multi-disciplinary Collaborations in Measurement of Human Motion

Comparative Medicine - OneHealth and Comparative Medicine Poster SessionBioengineering is a broad and rapidly-growing discipline defined as the application of engineering principles to biological systems. Although bioengineering is diverse in nature, the study of human movement is common to many bioengineering subdisciplines such as biomechanics and biometrics. Biomechanics is the science that examines the forces acting upon and within a biological structure and effects produced by such forces [1]. Measurement of ground reaction forces, limb motion, and muscle activation are fundamental research components in musculoskeletal biomechanics. Researchers in this field have used these measurements to quantify human gait, balance, and posture in a multitude of applications including age-related fall risk [2-4], muscle fatigue [5-7], and balance-related pathologies such as Parkinson's disease [8-10], and stroke [11, 12]. Additionally, these measurements play a vital role in computational biomechanics models. For example, the inverse dynamics method incorporates measured ground reaction forces and body motions to calculate the net reaction forces and torques acting on body joints [13]. Biometrics is the science of confirming or discovering individuals' identities based on their specific biological or behavioral traits [14]. Gait is one such modality which can be used for biometric identification. It is based on the uniqueness of an individual's locomotion patterns [15]. In addition, we are interested in high-speed video analyses of micro-saccades and blink reflexes for spoof-proofing of biometric identification systems, biometric identification, and psychometry. We have shown that startle blink intensity can be derived from high- speed video [18], enabling video-based psychophysiological biometrics for detection of subject-specific affective-cognitive information [19]. The Human Motion Laboratory at the University of Missouri - Kansas City is dedicated to measuring the characteristics of human motion. The lab includes a VICON MX 6-camera motion capture system, 4 AMTI OR6-6 force platforms, and a Delsys Myomonitor IV 16-channel wireless EMG system. This equipment represents an experimental infrastructure mutually supporting the biomechanics and biometrics research efforts of four research labs. The scope of these research efforts includes aging, affective computing, psychophysiological biometrics, orthopedics, and human dynamics pathology. The lab capitalizes on a synergistic environment for characterization and measurement of human movement and the interrelated nature of the research activities. The four main research areas that the Human Motion Laboratory supports are: •Computational Biomechanics •Biometrics of Human Motion •Experimental Biomechanics •Body Area Sensor Network

Spectroscopy of 13B via the 13C(t,3He) reaction at 115 AMeV

Gamow-Teller and dipole transitions to final states in 13B were studied via the 13C(t,3He) reaction at Et = 115 AMeV. Besides the strong Gamow-Teller transition to the 13B ground state, a weaker Gamow-Teller transition to a state at 3.6 MeV was found. This state was assigned a spin-parity of 3/2- by comparison with shell-model calculations using the WBP and WBT interactions which were modified to allow for mixing between nhw and (n+2)hw configurations. This assignment agrees with a recent result from a lifetime measurement of excited states in 13B. The shell-model calculations also explained the relatively large spectroscopic strength measured for a low-lying 1/2+ state at 4.83 MeV in 13B. The cross sections for dipole transitions up to Ex(13B)= 20 MeV excited via the 13C(t,3He) reaction were also compared with the shell-model calculations. The theoretical cross sections exceeded the data by a factor of about 1.8, which might indicate that the dipole excitations are "quenched". Uncertainties in the reaction calculations complicate that interpretation.Comment: 11 pages, 6 figure

Transversal directional filters for channel combining

A new concept for the design of power combiners based on matched directional filters is presented. The directional filters consist of individual balanced sections composed of hybrids and single resonators. Each of the sections corresponds to a pole of an all-pass function composed of the sum of S11 and S12 of the desired filter transfer function. A simple synthesis method is presented. The filter combiner has the advantage of ease of tunability because each pole is associated with a single resonator. Furthermore, no cross couplings are required to realize finite frequency transmission zeros

Interpreting and Reporting Results Based on Patient-Reported Outcomes

AbstractThis article deals with the incorporation of patient-reported outcomes (PROs) into clinical trials and focuses on issues associated with the interpretation and reporting of PRO data. The primary focus and context of this information relates to the evidentiary support and reporting for a labeling or advertising claim of a PRO benefit for a new or approved pharmaceutical product. This manuscript focuses on issues associated with assessing clinical significance and common pitfalls to avoid in presenting results related to PROs. Specifically, the questions addressed by this manuscript involve: What are the best methods to assess clinical significance for PROs? How should investigators present PRO data most effectively in a Food and Drug Administration (FDA) application? In labeling or in a scientific publication? Guidelinesfor interpreting clinical significance of PROs and for comprehensively reporting on the methods, measures and results of clinical trials that incorporate PROs are important for clinicians, regulatory agencies, and most of all to patients. Clear specifications for considering a finding on a PRO measure, as clinically meaningful, need to be determined by instrument developers and psychometricians; they need to be reported for all clinical trials involving PRO end points. Clinical trial reports need to be comprehensive, clear, and sufficient to enable any reader to understand the methods, PRO measures, statistical analysis, and results